07.10.19
Ampio Pharmaceuticals, Inc. has appointed Dan Stokely as Chief Financial Officer.
Mr. Stokely has more than 30 years of experience in finance and accounting and is a Certified Public Accountant. Dan has spent the majority of his career in positions of financial leadership within both publicly traded and privately-held pharmaceutical companies. Since 2012, Dan served as Executive Vice President and Chief Financial Officer of Sentynl Therapeutics as well as Vice President of Finance and Chief Accounting Officer of Victory Pharma.
Michael Macaluso, Ampio CEO, noted, "As we are already dosing patients in our pivotal Phase III trial of Ampion, as a biological treatment for adults with pain due to severe osteoarthritis of the knee (OAK), we sought a seasoned CFO with the experience and skills to advise us as we continue to move toward a future commercialization of Ampion."
Mr. Stokely has more than 30 years of experience in finance and accounting and is a Certified Public Accountant. Dan has spent the majority of his career in positions of financial leadership within both publicly traded and privately-held pharmaceutical companies. Since 2012, Dan served as Executive Vice President and Chief Financial Officer of Sentynl Therapeutics as well as Vice President of Finance and Chief Accounting Officer of Victory Pharma.
Michael Macaluso, Ampio CEO, noted, "As we are already dosing patients in our pivotal Phase III trial of Ampion, as a biological treatment for adults with pain due to severe osteoarthritis of the knee (OAK), we sought a seasoned CFO with the experience and skills to advise us as we continue to move toward a future commercialization of Ampion."
